Revvity (RVTY) to Release Quarterly Earnings on Monday

Revvity (NYSE:RVTY) is scheduled to announce its earnings results before the market opens on Monday, November 4th. Analysts expect the company to announce earnings of $1.13 per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Revvity (NYSE:RVTY) last released its quarterly earnings results on Monday, July 29th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.10. Revvity had a return on equity of 7.34% and a net margin of 6.26%. The firm had revenue of $691.70 million during the quarter, compared to analysts’ expectations of $690.33 million. During the same quarter in the prior year, the business earned $1.21 EPS. Revvity’s quarterly revenue was down 2.5% compared to the same quarter last year. On average, analysts expect Revvity to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Revvity Price Performance

Shares of RVTY stock opened at $116.33 on Monday. The firm has a fifty day simple moving average of $121.51 and a 200-day simple moving average of $113.51. The company has a market capitalization of $14.35 billion, a PE ratio of 96.14, a price-to-earnings-growth ratio of 3.27 and a beta of 1.05. Revvity has a twelve month low of $79.50 and a twelve month high of $128.15. The company has a current ratio of 2.27, a quick ratio of 1.98 and a debt-to-equity ratio of 0.40.

Revvity Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 7th. Shareholders of record on Friday, January 17th will be given a $0.07 dividend. The ex-dividend date is Friday, January 17th. This represents a $0.28 dividend on an annualized basis and a yield of 0.24%. Revvity’s payout ratio is currently 23.14%.

Insider Transactions at Revvity

In related news, insider Joel S. Goldberg sold 3,500 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $117.86, for a total transaction of $412,510.00. Following the completion of the transaction, the insider now owns 33,400 shares in the company, valued at $3,936,524. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, insider Joel S. Goldberg sold 3,500 shares of the business’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $117.86, for a total transaction of $412,510.00. Following the completion of the transaction, the insider now owns 33,400 shares of the company’s stock, valued at approximately $3,936,524. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Tajinder S. Vohra sold 2,154 shares of the stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $121.73, for a total transaction of $262,206.42. Following the completion of the sale, the insider now directly owns 19,652 shares in the company, valued at approximately $2,392,237.96. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 7,807 shares of company stock worth $937,576. 0.60% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

RVTY has been the subject of a number of analyst reports. Wells Fargo & Company began coverage on Revvity in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $130.00 price target for the company. Barclays raised shares of Revvity from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $125.00 to $140.00 in a research report on Tuesday, October 15th. Citigroup upped their price target on shares of Revvity from $135.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, July 30th. Leerink Partners raised their price objective on shares of Revvity from $130.00 to $135.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Finally, Bank of America upped their target price on shares of Revvity from $118.00 to $127.00 and gave the company a “neutral” rating in a research note on Tuesday, July 30th. Seven analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Revvity currently has an average rating of “Moderate Buy” and an average target price of $127.20.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.